EyeXam and GenieMD Announce Mobile Collaboration in Eye Care

EyeXam, the industry’s leading and patented mobile app, and GenieMD, a global provider of telemedicine solutions offering an accessible platform for connecting patients and providers around the world, today announced a joint venture introducing eyeXamVirtual, to modernize the eye care industry with an accessible and best-in-class telemedicine mobile solution.

Together, GenieMD and EyeXam’s resources will enable consumers easy access to eye care providers physically and virtually. GenieMD’s mission is to democratize health care globally, and this partnership will elevate eye care into a new era of telehealth engagement. Consumers will benefit from unprecedented and effortless access to eye care and doctor engagement, resulting in superior eye health. The venture partners GenieMD’s innovative telemedicine platform with EyeXam’s proprietary and self-guided method for measuring visual acuity using a mobile device. The impact of this partnership will create an unparalleled and proactive eye care solution, leading to a better overall eye health experience for consumers.

“We are excited to team up with EyeXam,” said Soheil Saadat, Ph.D., GenieMD’s founder, and CEO, “to deliver a unique telemedicine engagement model to vision care by combining EyeXam’s patented technology with our world-class cloud computing, big data, artificial intelligence and mobile technologies to provide the finest and fastest access to eye care patients, when they need it most.”

“We are grateful to partner with GenieMD,” Nikki Iravani, OD, optometrist and EyeXam founder and CEO commented, “to optimize the existing EyeXam app and bring the best in class in telemedicine to eye care. COVID-19 presented challenging circumstances and increased the demand for patients to visit with eye care providers virtually. EyeXam’s infrastructure and patented technology together with GenieMD’s platform accelerated the availability of virtual eye care for our patients.”

About GenieMD

SourceEyeXam™

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”